Dental implant for hypertensive patients as well as preparation method and application of dental implant

Abstract

The invention belongs to the technical field of implants and discloses a dental implant for hypertensive patients as well as a preparation method and application of the dental implant. The preparation method of the dental implant comprises the following steps: sequentially carrying out laser etching, acid etching and plasma treatment on the surface of a dental implant base body to obtain a pretreated dental implant base body; mixing the positively charged peptide amphiphilic molecules, losartan potassium and a first solvent to obtain a first mixed solution, and performing ultrasonic treatment and heating on the first mixed solution to obtain a losartan potassium loaded peptide nanofiber hydrogel precursor solution; mixing silk fibroin with the losartan potassium loaded peptide nanofiber hydrogel precursor solution to obtain a second mixed solution, coating the surface of a pretreated dental implant matrix with the second mixed solution, drying, soaking in a second solvent, and drying again to obtain the dental implant. The coating on the surface of the prepared dental implant contains losartan potassium, so that local administration can be realized, meanwhile, a long-term and stable slow-release effect is realized, and the dental implant is suitable for hypertensive patients.

Description

Technical Field

[0001] This invention belongs to the field of implant technology, and specifically relates to a dental implant for patients with hypertension, its preparation method, and its application. Background Technology

[0002] Titanium and its alloys are widely used as implant materials in orthopedics and dentistry due to their excellent biocompatibility and mechanical properties. Currently, dental implants have become the preferred treatment for missing teeth. First-generation implants are made by turning or polishing to create a smooth surface, making the procedure simple, but they have poor osseointegration. Due to insufficient bone contact area, the implant failure rate is as high as 35%, and they have been largely phased out clinically. Second-generation implants use hydroxyapatite coatings and titanium paste coatings, with high-temperature spraying of bioactive ceramics to enhance bone affinity; however, the high-purity coating is easily absorbed, leading to weakened metal-bone interface bonding in the later stages. Plasma-sprayed titanium particles form a porous layer with a porosity >50%, but there is a risk of coating peeling, and high-temperature processes (>1000℃) damage the stability of the substrate, and the coating-substrate interface is prone to failure.

[0003] With the increasing aging of the global population, osteoporosis and hypertension have become major chronic diseases affecting public health. The implant failure rate in hypertensive patients is 38% higher than in healthy individuals because excessive activation of the renin-angiotensin system (RAS) inhibits bone formation. Currently, there is a lack of dental implants specifically designed for hypertensive patients. Losartan potassium, a common antihypertensive drug, is also an angiotensin II receptor antagonist (ARB). It restores bone remodeling balance by blocking the type 1 receptor (AT1R) of angiotensin II, reducing its inhibition of osteoblast differentiation, and decreasing osteoclast activity. Hypertensive patients often have abnormal bone metabolism, and losartan potassium can specifically correct this pathological condition.

[0004] Currently, the main challenges in applying losartan potassium to implants are: 1. Systemic administration: Oral losartan potassium acts systemically and cannot achieve an effective concentration at the implant site; 2. Difficulty in local administration: If the implant is simply loaded with the drug, the drug will be released rapidly (burst release effect), which cannot achieve a long-term, stable sustained-release effect and is difficult to cover the critical period of osseointegration (several weeks to several months). Summary of the Invention

[0005] The present invention aims to at least solve one of the technical problems existing in the prior art. To this end, the present invention proposes a dental implant for patients with hypertension, its preparation method, and its application; the coating on the surface of the dental implant prepared by the present invention contains losartan potassium, which can achieve local drug delivery and a long-term, stable sustained-release effect, making it suitable for patients with hypertension.

[0006] A first aspect of the present invention provides a method for preparing a dental implant, comprising the following steps: The surface of the dental implant substrate is sequentially subjected to laser etching, acid etching, and plasma treatment to obtain a pretreated dental implant substrate. A first mixture is obtained by mixing a positively charged amphiphilic peptide molecule, losartan potassium, and a first solvent. The first mixture is then sonicated and heated to obtain a peptide nanofiber hydrogel precursor solution loaded with losartan potassium.

[0007] A second mixture is obtained by mixing silk fibroin with the peptide nanofiber hydrogel precursor solution loaded with losartan potassium. The second mixture is then coated on the surface of the pretreated dental implant matrix, dried, soaked in a second solvent, and dried again to form a hydrogel coating on the surface of the pretreated dental implant matrix, thereby obtaining the dental implant.

[0008] In some embodiments of the present invention, the dental implant matrix is ​​made of pure titanium or titanium alloy.

[0009] In some embodiments of the present invention, before performing the laser etching, a step of cleaning and degreasing the dental implant substrate is included.

[0010] In some embodiments of the present invention, the power of the laser etching is 10-30W, preferably 16-20W.

[0011] In some embodiments of the present invention, the acid etching solution used is a mixture of hydrochloric acid solution, sulfuric acid solution and hydrofluoric acid solution.

[0012] In some embodiments of the present invention, the mass ratio of the hydrochloric acid solution, sulfuric acid solution and hydrofluoric acid solution is (3-4):(2-3):(1-2).

[0013] In some embodiments of the present invention, the mass concentration of the hydrochloric acid solution is 30-36%, the mass concentration of the sulfuric acid solution is 90-98%, and the mass concentration of the hydrofluoric acid solution is 30-40%.

[0014] In some embodiments of the present invention, the acid etching temperature is 85-100°C.

[0015] In some embodiments of the present invention, the acid etching time is 5-15 minutes.

[0016] In some embodiments of the present invention, the power of the plasma treatment is 120-140W.

[0017] In some embodiments of the present invention, the atmosphere for plasma treatment is an inert atmosphere.

[0018] In some embodiments of the present invention, the inert atmosphere includes argon.

[0019] In some embodiments of the present invention, the vacuum degree of the plasma treatment is 10-20 Pa.

[0020] In some embodiments of the present invention, the plasma treatment time is 20-40 seconds.

[0021] In some embodiments of the present invention, the first solvent includes water.

[0022] In some embodiments of the present invention, the concentration of the positively charged amphiphilic peptide molecule in the first mixture is 10-20 mg / mL.

[0023] In some embodiments of the present invention, the concentration of losartan potassium in the first mixture is 10-15 mg / mL.

[0024] In some embodiments of the present invention, the temperature of the ultrasound is 40-50°C.

[0025] In some embodiments of the present invention, the duration of the ultrasound is 20-30 minutes.

[0026] In some embodiments of the present invention, the power of the ultrasound is 40-60W.

[0027] In some embodiments of the present invention, the heating temperature is 80-100°C.

[0028] In some embodiments of the present invention, the heating time is 10-30 minutes.

[0029] In some embodiments of the present invention, the concentration of the silk fibroin in the second mixture is 1-1.5 mg / mL.

[0030] In some embodiments of the present invention, the soaking time in the second solvent is 10-20 minutes.

[0031] In some embodiments of the present invention, the coating is performed using a rotary drop method, in which the pretreated dental implant substrate is placed horizontally and rotated at a speed of 1000-1500 rpm, and a second mixture is dropped onto its surface, repeated 1-3 times.

[0032] In some embodiments of the present invention, the second solvent comprises an ethanol solution. The present invention uses ethanol solution soaking to alter the structure of silk fibroin, making it less susceptible to degradation.

[0033] In some embodiments of the present invention, the mass concentration of the ethanol solution is 70-80%.

[0034] In some embodiments of the present invention, the drying temperature is 60-80°C.

[0035] In a second aspect, the present invention provides a dental implant prepared by the preparation method described in the first aspect of the present invention.

[0036] A third aspect of the invention provides the use of the dental implant described in the second aspect of the invention in the preparation of dental implants for patients with hypertension.

[0037] Compared with the prior art, the beneficial effects of the present invention are as follows: (1) The present invention can provide a rough surface to facilitate bone formation and regular micron-sized pits as uniform drug-carrying containers through laser etching and acid etching.

[0038] (2) Losartan potassium sustained release: Losartan potassium is supported by peptide nanofibers to achieve controlled sustained release (composed of a nanofiber network formed by the self-assembly of positively charged peptide amphiphilic molecules, which encapsulates losartan potassium molecules); the preferred sequence of the peptide amphiphilic molecules is palmitoyl-VVVAAAKKK (PA+), and the lysine (K) residue at its end provides a positive charge, which generates strong electrostatic adsorption with the negatively charged losartan potassium molecules (containing a tetrazolium group), thereby achieving long-term sustained release of the drug.

[0039] (3) Targeted regulation: Losartan potassium is released locally at the implant-bone interface, which precisely inhibits local angiotensin II receptors, blocks the RAS pathway, promotes osteogenic differentiation, and avoids the side effects of systemic medication; in addition, after being metabolized by organs, losartan potassium has a blood pressure regulating effect and is suitable for people with hypertension. Attached Figure Description

[0040] Figure 1 The image shows the surface microstructure of the dental implant substrate in Example 1 after laser etching and acid etching. Figure 2 This is a microscopic morphology image of the surface of the dental implant prepared in Example 1. Detailed Implementation

[0041] To enable those skilled in the art to more clearly understand the technical solutions described in this invention, the following embodiments are provided for illustration. It should be noted that the following embodiments do not constitute a limitation on the scope of protection claimed by this invention.

[0042] Unless otherwise specified, the raw materials, reagents or devices used in the following examples are available from conventional commercial sources or can be obtained by existing known methods.

[0043] Peptide amphiphilic molecule (sequence C) 16 -V3A3K3 was purchased from Hangzhou Gutuo Biotechnology Co., Ltd.

[0044] The silk fibroin sponge was purchased from Suzhou Silmet Biotechnology Co., Ltd.

[0045] Losartan potassium powder (99%) was purchased from Shanghai Maclean Biochemical Technology Co., Ltd.

[0046] Room temperature refers to 25±2℃.

[0047] Example 1 A method for preparing dental implants for patients with hypertension includes the following steps: (1) The pure titanium dental implant matrix is ​​cleaned and degreased, and then laser etched at a power of 20W; (2) The pure titanium dental implant matrix after laser etching is immersed in acid solution for acid etching; wherein the acid solution is a mixed solution composed of hydrochloric acid solution with a mass concentration of 36%, sulfuric acid solution with a mass concentration of 98%, and hydrofluoric acid solution with a mass concentration of 40% in a mass ratio of 3:2:1, the acid etching temperature is 90℃, and the acid etching time is 10min; (3) The pure titanium dental implant matrix after acid etching is placed in a vacuum plasma machine for hydrophilization treatment to facilitate the preparation of the subsequent hydrogel coating; the plasma treatment power is 131W, the inert atmosphere is argon, the vacuum degree is controlled at 15Pa, and the plasma treatment time is 30s. (4) The positively charged amphiphilic peptide molecule (PA+) and losartan potassium powder were dissolved in deionized water to obtain the first mixture (the concentration of PA+ was 20 mg / mL and the concentration of losartan potassium was 15 mg / mL). The first mixture was ultrasonically treated at 45°C and 50 W for 25 min, then heated at 80°C for 30 min, and then cooled to room temperature to allow PA+ to co-assemble, thus obtaining the peptide nanofiber hydrogel precursor solution loaded with losartan potassium. (5) Mix the silk fibroin sponge with the peptide nanofiber hydrogel precursor solution loaded with losartan potassium to obtain a second mixture (the concentration of silk fibroin is 1 mg / mL). Then, place the pure titanium dental implant matrix after plasma treatment in step (3) horizontally (connected by a conventional motor and clamp) and rotate it at a speed of 1000 rpm. At the same time, drop the second mixture onto its surface. Repeat this process 3 times. Then, dry it in an oven at 60°C. Then, soak it in an 80 wt% ethanol aqueous solution for 15 min and dry it again. A hydrogel coating is formed on the surface of the pure titanium dental implant matrix, and the dental implant is obtained.

[0048] In the fabrication process of this embodiment, after laser etching and acid etching, the scanning electron microscope (SEM) results of the pure titanium dental implant substrate surface are as follows: Figure 1 As shown, micron-sized pits have formed on the surface; The final dental implant obtained through step (5) has the following SEM results on its surface: Figure 2As shown, a coating has been formed on the surface.

[0049] Example 2 A method for preparing dental implants for patients with hypertension includes the following steps: (1) The pure titanium dental implant matrix is ​​cleaned and degreased, and then laser etched at a power of 18W; (2) The pure titanium dental implant matrix after laser etching is immersed in acid solution for acid etching; wherein the acid solution is a mixed solution composed of hydrochloric acid solution with a mass concentration of 36%, sulfuric acid solution with a mass concentration of 98%, and hydrofluoric acid solution with a mass concentration of 40% in a mass ratio of 4:3:2, the acid etching temperature is 85℃, and the acid etching time is 15min; (3) The pure titanium dental implant matrix after acid etching is placed in a vacuum plasma machine for hydrophilization treatment to facilitate the preparation of the subsequent hydrogel coating; the plasma treatment power is 131W, the inert atmosphere is argon, the vacuum degree is controlled at 10Pa, and the plasma treatment time is 40s. (4) The positively charged amphiphilic peptide molecule (PA+) and losartan potassium powder were dissolved in deionized water to obtain the first mixture (the concentration of PA+ was 10 mg / mL and the concentration of losartan potassium was 10 mg / mL). The first mixture was ultrasonically treated at 45°C and 50 W for 25 min, then heated at 80°C for 30 min, and then cooled to room temperature to allow PA+ to co-assemble, thus obtaining the peptide nanofiber hydrogel precursor solution loaded with losartan potassium. (5) Mix the silk fibroin sponge with the peptide nanofiber hydrogel precursor solution loaded with losartan potassium to obtain a second mixture (the concentration of silk fibroin is 1 mg / mL). Then, place the pure titanium dental implant matrix after plasma treatment in step (3) horizontally (connected by a conventional motor and clamp) and rotate it at a speed of 1000 rpm. At the same time, drop the second mixture onto its surface. Repeat this process 3 times. Then, dry it in an oven at 60°C. Then, soak it in an 80 wt% ethanol aqueous solution for 15 min and dry it again. A hydrogel coating is formed on the surface of the pure titanium dental implant matrix, and the dental implant is obtained.

[0050] Example 3 A method for preparing dental implants for patients with hypertension includes the following steps: (1) The pure titanium dental implant matrix is ​​cleaned and degreased, and then laser etched at a power of 16W; (2) The pure titanium dental implant matrix after laser etching is immersed in acid solution for acid etching; wherein the acid solution is a mixed solution composed of hydrochloric acid solution with a mass concentration of 36%, sulfuric acid solution with a mass concentration of 98%, and hydrofluoric acid solution with a mass concentration of 40% in a mass ratio of 3:2:1, the acid etching temperature is 100℃, and the acid etching time is 5min; (3) The pure titanium dental implant matrix after acid etching is placed in a vacuum plasma machine for hydrophilization treatment to facilitate the preparation of the subsequent hydrogel coating; the plasma treatment power is 131W, the inert atmosphere is argon, the vacuum degree is controlled at 10Pa, and the plasma treatment time is 40s. (4) The positively charged amphiphilic peptide molecule (PA+) and losartan potassium powder were dissolved in deionized water to obtain the first mixture (the concentration of PA+ was 20 mg / mL and the concentration of losartan potassium was 15 mg / mL). The first mixture was ultrasonically treated at 45°C and 50 W for 25 min, then heated at 80°C for 30 min, and then cooled to room temperature to allow PA+ to co-assemble, thus obtaining the peptide nanofiber hydrogel precursor solution loaded with losartan potassium. (5) Mix the silk fibroin sponge with the peptide nanofiber hydrogel precursor solution loaded with losartan potassium to obtain a second mixture (the concentration of silk fibroin is 1.2 mg / mL). Then place the pure titanium dental implant matrix after plasma treatment in step (3) horizontally (connected by a conventional motor and clamp) and rotate it at a speed of 1500 rpm. At the same time, drop the second mixture onto its surface. Repeat 3 times. Then dry it in an oven at 60°C. Then soak it in 80 wt% ethanol aqueous solution for 15 min and dry it again. A hydrogel coating is formed on the surface of the pure titanium dental implant matrix, and the dental implant is obtained.

[0051] Comparative Example 1 (The difference from Example 1 is that no laser and acid etching treatment was performed) A method for preparing dental implants for patients with hypertension includes the following steps: (1) The pure titanium dental implant matrix is ​​cleaned and degreased, and then placed in a vacuum plasma machine for treatment; the plasma treatment power is 131W, the inert atmosphere is argon, the vacuum degree is controlled at 15Pa, and the plasma treatment time is 30s. (2) The positively charged amphiphilic peptide molecule (PA+) and losartan potassium powder were dissolved in deionized water to obtain the first mixture (the concentration of PA+ was 20 mg / mL and the concentration of losartan potassium was 15 mg / mL). The first mixture was ultrasonically treated at 45°C and 50 W for 25 min, then heated at 80°C for 30 min, and then cooled to room temperature to allow PA+ to co-assemble, thus obtaining the peptide nanofiber hydrogel precursor solution loaded with losartan potassium. (3) Mix the silk fibroin sponge with the peptide nanofiber hydrogel precursor solution loaded with losartan potassium to obtain a second mixture (the concentration of silk fibroin is 1 mg / mL). Then place the pure titanium dental implant matrix after plasma treatment in step (1) horizontally and rotate it at a speed of 1000 rpm. At the same time, drop the second mixture on its surface. Repeat 3 times. Then put it in an oven to dry at 60°C. Then soak it in 80 wt% ethanol aqueous solution for 15 min and dry it again to obtain the dental implant.

[0052] Comparative Example 2 (The difference from Example 1 is that no plasma treatment was performed) A method for preparing dental implants for patients with hypertension includes the following steps: (1) The pure titanium dental implant matrix is ​​cleaned and degreased, and then laser etched at a power of 20W; (2) The pure titanium dental implant matrix after laser etching is immersed in acid solution for acid etching; wherein the acid solution is a mixed solution composed of hydrochloric acid solution with a mass concentration of 36%, sulfuric acid solution with a mass concentration of 98%, and hydrofluoric acid solution with a mass concentration of 40% in a mass ratio of 3:2:1, the acid etching temperature is 90℃, and the acid etching time is 10min; (3) The positively charged amphiphilic peptide molecule (PA+) and losartan potassium powder were dissolved in deionized water to obtain the first mixture (the concentration of PA+ was 20 mg / mL and the concentration of losartan potassium was 15 mg / mL). The first mixture was ultrasonically treated at 45°C and 50 W for 25 min, then heated at 80°C for 30 min, and then cooled to room temperature to allow PA+ to co-assemble, thus obtaining the peptide nanofiber hydrogel precursor solution loaded with losartan potassium. (4) Mix the silk fibroin sponge with the peptide nanofiber hydrogel precursor solution loaded with losartan potassium to obtain a second mixture (the concentration of silk fibroin is 1 mg / mL). Then place the pure titanium dental implant matrix after acid etching treatment in step (2) horizontally and rotate it at a speed of 1000 rpm. At the same time, drop the second mixture on its surface. Repeat 3 times. Then put it in an oven to dry at 60°C. Then soak it in 80 wt% ethanol aqueous solution for 15 min and dry it again to obtain the dental implant.

[0053] Comparative Example 3 (The difference from Example 1 is that no positively charged amphiphilic peptide molecule was added) A method for preparing dental implants for patients with hypertension includes the following steps: (1) The pure titanium dental implant matrix is ​​cleaned and degreased, and then laser etched at a power of 20W; (2) The pure titanium dental implant matrix after laser etching is immersed in acid solution for acid etching; wherein the acid solution is a mixed solution composed of hydrochloric acid solution with a mass concentration of 36%, sulfuric acid solution with a mass concentration of 98%, and hydrofluoric acid solution with a mass concentration of 40% in a mass ratio of 3:2:1, the acid etching temperature is 100℃, and the acid etching time is 10min; (3) The pure titanium dental implant matrix after acid etching is placed in a vacuum plasma machine for hydrophilization treatment to facilitate the preparation of the subsequent hydrogel coating; the plasma treatment power is 131W, the inert atmosphere is argon, the vacuum degree is controlled at 15Pa, and the plasma treatment time is 30s. (4) Dissolve losartan potassium powder in deionized water to obtain losartan potassium solution; (5) Mix the silk fibroin sponge with losartan potassium solution to obtain a mixture (the concentration of silk fibroin is 1 mg / mL). Then place the pure titanium dental implant matrix after plasma treatment in step (3) horizontally and rotate it at a speed of 1000 rpm. At the same time, drop the mixture onto its surface. Repeat this process 3 times. Then dry it in an oven at 60°C. Then soak it in 80 wt% ethanol aqueous solution for 15 min and dry it again to obtain the dental implant.

[0054] Comparative Example 4 (The difference from Example 1 is that no silk fibroin sponge was added) A method for preparing dental implants for patients with hypertension includes the following steps: (1) The pure titanium dental implant matrix is ​​cleaned and degreased, and then laser etched at a power of 20W; (2) The pure titanium dental implant matrix after laser etching is immersed in acid solution for acid etching; wherein the acid solution is a mixed solution composed of hydrochloric acid solution with a mass concentration of 36%, sulfuric acid solution with a mass concentration of 98%, and hydrofluoric acid solution with a mass concentration of 40% in a mass ratio of 3:2:1, the acid etching temperature is 100℃, and the acid etching time is 10min; (3) The pure titanium dental implant matrix after acid etching is placed in a vacuum plasma machine for hydrophilization treatment to facilitate the preparation of the subsequent hydrogel coating; the plasma treatment power is 131W, the inert atmosphere is argon, the vacuum degree is controlled at 15Pa, and the plasma treatment time is 30s. (4) The positively charged amphiphilic peptide molecule (PA+) and losartan potassium powder were dissolved in deionized water to obtain a mixture (the concentration of PA+ was 20 mg / mL and the concentration of losartan potassium was 15 mg / mL). The mixture was ultrasonically treated at 45°C and 50 W for 25 min, then heated at 80°C for 30 min, and then cooled to room temperature to allow PA+ to co-assemble, thus obtaining a peptide nanofiber hydrogel precursor solution loaded with losartan potassium. (5) Place the pure titanium dental implant matrix after plasma treatment in step (3) horizontally and rotate it at a speed of 1000 rpm. At the same time, drop a peptide nanofiber hydrogel precursor solution loaded with losartan potassium onto its surface. Repeat this process 3 times. Then dry it in an oven at 60°C. After that, soak it in an 80wt% ethanol aqueous solution for 15 minutes and dry it again to obtain the dental implant.

[0055] Drug sustained-release performance test Dental implants prepared in Examples 1-3 and Comparative Examples 1-4 were used as samples. Each sample was placed in a PBS buffer (Na2HPO4: 1.44 g / L, KH2PO4: 0.24 g / L, NaCl: 8 g / L, KCl: 0.2 g / L) release medium and oscillated at 37°C. Samples were taken at predetermined time points, and the absorbance at 239 nm was detected using a UV spectrophotometer to calculate the cumulative release of losartan potassium.

[0056] A longer sustained-release time and a larger sustained-release amount result in superior sustained-release performance. The test results are shown in Table 1.

[0057] Table 1

[0058] As shown in Table 1, the cumulative release of losartan potassium by the dental implants prepared in Examples 1-3 after week 5 was significantly higher than that in Comparative Examples 1-4, indicating that the dental implants of the present invention can effectively load losartan potassium and achieve long-term sustained release of losartan potassium. When the cumulative release no longer changes, it indicates that the release has stopped. A low release indicates a low drug loading in the coating and poor sustained release performance.

[0059] The preferred embodiments of the present invention have been described in detail above, but the present invention is not limited to the embodiments described. Those skilled in the art can make various equivalent modifications or substitutions without departing from the spirit of the present invention, and these equivalent modifications or substitutions are all included within the scope defined by the claims of this application.

Claims

1. A method for preparing a dental implant, characterized in that, Includes the following steps: The surface of the dental implant substrate is sequentially subjected to laser etching, acid etching, and plasma treatment to obtain a pretreated dental implant substrate. A first mixture is obtained by mixing a positively charged amphiphilic peptide molecule, losartan potassium, and a first solvent. The first mixture is then sonicated and heated to obtain a peptide nanofiber hydrogel precursor solution loaded with losartan potassium. A second mixture is obtained by mixing silk fibroin with the peptide nanofiber hydrogel precursor solution loaded with losartan potassium. The second mixture is then coated on the surface of the pretreated dental implant matrix, dried, soaked in a second solvent, and dried again to form a hydrogel coating on the surface of the pretreated dental implant matrix, thereby obtaining the dental implant.

2. The preparation method according to claim 1, characterized in that, The power of the laser etching is 10-30W.

3. The preparation method according to claim 1, characterized in that, The acid etching solution used is a mixture of hydrochloric acid solution, sulfuric acid solution and hydrofluoric acid solution; and / or, the acid etching temperature is 85-100℃; and / or, the acid etching time is 5-15 min.

4. The preparation method according to claim 1, characterized in that, The power of the plasma treatment is 120-140W; and / or, the atmosphere of the plasma treatment is an inert atmosphere; and / or, the vacuum degree of the plasma treatment is 10-20Pa; and / or, the time of the plasma treatment is 20-40s.

5. The preparation method according to claim 1, characterized in that, In the first mixture, the concentration of the positively charged amphiphilic peptide molecule is 10-20 mg / mL, and the concentration of losartan potassium is 10-15 mg / mL.

6. The preparation method according to claim 1, characterized in that, The heating temperature is 80-100℃; and / or the heating time is 10-30 min.

7. The preparation method according to claim 1, characterized in that, In the second mixture, the concentration of the silk fibroin is 1-1.5 mg / mL.

8. The preparation method according to claim 1, characterized in that, The first solvent includes water; and / or the second solvent includes an ethanol solution.

9. A dental implant, characterized in that, Prepared by the preparation method according to any one of claims 1-8.

10. The use of the dental implant of claim 9 in the preparation of dental implants for patients with hypertension.

Images